@article{PAR00023799,
  title = {{E}fficacy of dihydroartemisinin/piperaquine in patients with non-complicated {P}lasmodium falciparum malaria in {Y}aounde, {C}ameroon},
  author = {{M}airet-{K}hedim, {M}. and {N}sango, {S}. and {N}gou, {C}. and {M}enard, {S}. and {R}oesch, {C}. and {K}him, {N}. and {S}run, {S}. and {I}riart, {X}. and {L}anot, {T}. and {O}tam, {L}. and {A}bega, {F}. and {A}yong, {L}. and {M}orlais, {I}sabelle and {G}andia, {P}. and {W}itkowski, {B}. and {B}erry, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {D}ihydroartemisinin/piperaquine is increasingly used for the treatment of uncomplicated {P}lasmodium falciparum malaria in {A}frica. {T}he efficacy of this combination in {C}ameroon is poorly documented, while resistance to dihydroartemisinin/piperaquine readily spreads in {S}outheast {A}sia. {O}bjectives: {T}his study evaluated the clinical efficacy of dihydroartemisinin/piperaquine in {C}ameroon, as well as the molecular profile and phenotypic susceptibility of collected isolates to dihydroartemisinin and piperaquine. {P}atients and methods: {D}ihydroartemisinin/piperaquine efficacy in 42days was followed-up for 138 patients presenting non-complicated falciparum malaria. {P}iperaquine concentration was determined at day 7 for 124 patients. kelch13 gene polymorphisms (n=150) and plasmepsin2 gene amplification (n=148) were determined as molecular markers of resistance to dihydroartemisinin and piperaquine, respectively. {P}arasite susceptibility to dihydroartemisinin and piperaquine was determined using validated in vitro survival assays. {R}esults: {T}he efficacy of dihydroartemisinin/piperaquine treatment was 100% after {PCR} correction. {T}he reinfections were not associated with a variation of piperaquine concentration at day 7. {N}inety-six percent (144/150) of the samples presented a {WT} allele of the kelch13 gene. {T}wo percent (3/150) presented the non-synonymous mutation {A}578{S}, which is not associated with resistance to dihydroartemisinin. {N}o duplication of the plasmepsin2 gene was observed (0/148). {A}ll the samples tested in vitro by survival assays (n=87) were susceptible to dihydroartemisinin and piperaquine. {C}onclusions: {D}ihydroartemisinin/piperaquine has demonstrated excellent therapeutic efficacy with no evidence of emerging artemisinin or piperaquine resistance in {Y}aounde, {C}ameroon. {T}his observation suggests that dihydroartemisinin/piperaquine could be a sustainable therapeutic solution for {P}. falciparum malaria if implemented in areas previously free of artemisinin- and piperaquine-resistant parasites, unlike {S}outheast {A}sia.},
  keywords = {{CAMEROUN} ; {YAOUNDE}},
  booktitle = {},
  journal = {{J}ournal of {A}ntimicrobial {C}hemotherapy},
  volume = {76},
  numero = {11},
  pages = {3037--3044},
  ISSN = {0305-7453},
  year = {2021},
  DOI = {10.1093/jac/dkab281},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00023799},
}